相关实验视频

Updated: Jun 30, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

新的eGFR方程:对心脏病学家和种族不平等的影响

Nali Gillespie¹, Rajesh Mohandas¹

¹Section of Nephrology & Hypertension, Department of Medicine, Louisiana State University School of Medicine-New Orleans, United States of America.

American heart journal plus : cardiology research and practice

|March 21, 2024

概括

现在已经广泛采用了一种新的估计膜过率 (eGFR) 方程,去除了种族. 这一变化可能会影响心血管保健的差异,并强调需要包容性临床试验和基因组医学.

科学领域:

腎臟病學 (nephrology) 是一種醫學.
心脏病学心脏病学
基因组医学是基因组医学.

背景情况:

一个新的估计膜过率 (eGFR) 方程,不包括种族,已经获得了认可和采用.
种族在eGFR计算中的使用正在被重新评估,因为它的性质是社会结构和生物变异性的糟糕代理.

研究的目的:

讨论新的无种族eGFR方程背后的逻辑.
探索这个新的方程对心脏病学家的影响.
分析对心血管保健差异的潜在影响.

主要方法:

文献综述和分析新eGFR方程的含义.
讨论种族作为医学评估中的社会结构的作用.
检查包容性临床试验和基因组医学的潜在好处.

主要成果:

新的eGFR方程旨在提高准确性并减少差异.
从eGFR计算中删除种族可能会影响患者风险分层和治疗决策.
这一转变强调了需要更精确,个性化医疗方法的需要.

结论:

采用无种族的eGFR方程是朝着公平医疗保健迈出的重要一步.
解决心血管保健方面的差异需要采取多方面的方法,包括多元化的临床试验参与和基因组医学的进步.
个性化医疗有望减少临床结果中的不平等.

关键词:

心血管疾病是什么心血管疾病慢性脏疾病慢性脏疾病不公平不公平不公平种族差异是种族差异.

更多相关视频

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...